Catalog No.
DHJ85304
Expression system
Mammalian Cells
Species reactivity
Human
Isotype
Fusion - [TNFRSF13B (tumor necrosis factor receptor (TNFR) superfamily member 13B, TACI, transmembrane activator and CAML Interactor)]2 - IGHG1 Fc (Fragment constant)
Target
BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9Y275
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
RC18, CAS: 2136630-26-5
Clone ID
Telitacicept
Response to telitacicept in optic neuritis associated with Sjogren's syndrome: a case report and literature review., PMID:40515854
Telitacicept as double-targeted therapy for myasthenia gravis coexisting with connective tissue disease: three case reports., PMID:40496856
Dual BLyS/APRIL targeted therapy with telitacicept in rituximab-refractory SLE-associated neuromyelitis optica spectrum disorder: a case report., PMID:40491913
Telitacicept for lupus nephritis with BAFF and APRIL double positivity in children: a case report., PMID:40420262
Single cell analysis identified IFN signaling activation contributes to the pathogenesis of pediatric steroid-sensitive nephrotic syndrome., PMID:40413560
Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report., PMID:40375991
Letter to Editor: Efficacy of Telitacicept in the Treatment of Sjögren's Syndrome-Associated Interstitial Lung Disease: A Case Report., PMID:40317919
Effects of telitacicept in SLE patients with antiphospholipid antibody positivity: a retrospective self-controlled case series., PMID:40317459
Case Report: A case of membranous nephropathy associated with primary Sjögren's syndrome treated with telitacicept., PMID:40292296
Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review., PMID:40265191
Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights., PMID:40263911
Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: A retrospective real-world study., PMID:40254770
Efficacy and Safety of Telitacicept as an Add-On Therapy for Refractory Immunoglobulin A Nephropathy or Immunoglobulin A Vasculitis Nephropathy in Children., PMID:40225367
Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series., PMID:40224392
Telitacicept as a BAFF/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis., PMID:40214779
Telitacicept: A New Therapy for the Treatment of Optic Neuromyelitis Spectrum Disease Associated with Other Autoimmune Disorders., PMID:40196354
Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect., PMID:40196119
Successful treatment of refractory systemic lupus erythematosus-associated immune thrombocytopenia with drug-induced liver injury with telitacicept: a case report and review., PMID:40176813
Efficacy and safety of telitacicept in patients with class III-V lupus nephritis: A real-world retrospective cohort study., PMID:40174338
Evaluation of the efficacy and safety of belimumab and telitacicept in patients with systemic lupus erythematosus: results from a retrospective, observational study., PMID:40172681
Case Report: A refractory unusual tetrad of overlap syndrome involving rheumatoid arthritis, Sjögren's syndrome, autoimmune hepatitis, and type 1 renal tubular acidosis, successfully treated with a BLyS/APRIL dual inhibitor., PMID:40170868
Case Series: Effectiveness and Safety of Telitacicept in Chinese Patients With Primary Sjögren's Disease., PMID:40123315
Effective treatment of immune mediated peripheral neuropathy with Ofatumumab - A case report., PMID:40121773
Real world data on dual BLyS/APRIL inhibition with telitacicept for lupus nephritis., PMID:40052354
Telitacicept use in children with IgA vasculitis nephritis: preliminary observations., PMID:40042623
Successful outcome of a refractory IgA vasculitis nephritis in children treated with telitacicept., PMID:40025360
Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA receptor encephalitis and MOG-associated demyelination: a case report and literature review., PMID:39981240
Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review., PMID:39958611
Effectiveness and safety of telitacicept in patients with systemic lupus erythematosus: a single center, retrospective, real-world study., PMID:39903405
Telitacicept for systemic lupus erythematosus with post‑surgical papillary thyroid carcinoma: A case report., PMID:39882332
Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis., PMID:39867893
Exploring telitacicept in a patient with pemphigus vulgaris., PMID:39820725
Efficacy and safety of telitacicept in IgA nephropathy: a real-world study., PMID:39780498
Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study., PMID:39762087
The effectiveness of telitacicept in patients with systemic lupus erythematosus: A retrospective, real-world study., PMID:39715630
Telitacicept for refractory cystitis associated with severe systemic lupus erythematosus: A case report., PMID:39705664
[Ovarian function in patients of childbearing age with systemic lupus erythematosus]., PMID:39690764
Effectiveness and safety of Belimumab and Telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study., PMID:39680262
The Latest Progress in the Application of Telitacicept in Autoimmune Diseases., PMID:39664967
Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review., PMID:39624088
Neuromyelitis optica spectrum disorder with ultra-longitudinally extensive transverse myelitis: A case report and literature review., PMID:39559196
Single-dose telitacicept therapy for refractory idiopathic membranous nephropathy: A case series., PMID:39512788
Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study., PMID:39495163
Combination treatment with telitacicept, mycophenolate mofetil and glucocorticoids for immunoglobulin A nephropathy: A case report., PMID:39417050
Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study., PMID:39391591
Efficacy and Safety of Telitacicept in IgA Nephropathy: A Retrospective, Multicenter Study., PMID:39250892
Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases., PMID:39146891
Efficacy and safety of telitacicept in patients with lupus nephritis., PMID:39091632
Good efficacy achieved by telitacicept in treatment of systemic lupus erythematosus with alopecia areata., PMID:39050148
Current understanding and new insights in the treatment of IgA nephropathy., PMID:38958055
For research use only. Not for human or drug use.
